Researchers from the Parkinson’s Progression Markers Initiative have developed a test to detect alpha-synuclein, a protein that accumulates in the brains of patients with Parkinson’s disease, in cerebrospinal fluid. The assay, called SYNTap and recently commercialized by Amprion, was able to distinguish patients with Parkinson’s disease from non-Parkinson’s patients with an 88% accuracy rate and 96% specificity. The test could potentially be used to diagnose the disease before patients develop symptoms and help researchers find better ways to treat it. The SYNTap test was granted breakthrough-device designation by the U.S. FDA in February 2022.
Article written by Helen Floersh